Commonwealth Equity Services LLC Has $174,000 Position in Galectin Therapeutics Inc. (NASDAQ:GALT)

Commonwealth Equity Services LLC lowered its holdings in Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) by 72.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 134,518 shares of the company's stock after selling 348,746 shares during the quarter. Commonwealth Equity Services LLC owned 0.21% of Galectin Therapeutics worth $174,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. PNC Financial Services Group Inc. acquired a new position in Galectin Therapeutics during the 4th quarter worth $26,000. Inspire Advisors LLC grew its stake in shares of Galectin Therapeutics by 86.3% during the fourth quarter. Inspire Advisors LLC now owns 21,095 shares of the company's stock worth $27,000 after purchasing an additional 9,772 shares during the period. HighTower Advisors LLC acquired a new position in Galectin Therapeutics in the fourth quarter valued at about $29,000. Stratos Wealth Partners LTD. grew its position in shares of Galectin Therapeutics by 27.4% during the 4th quarter. Stratos Wealth Partners LTD. now owns 51,550 shares of the company's stock worth $66,000 after buying an additional 11,100 shares during the period. Finally, Wealth Enhancement Advisory Services LLC raised its position in shares of Galectin Therapeutics by 46.4% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 51,369 shares of the company's stock valued at $66,000 after acquiring an additional 16,271 shares during the period. 11.68% of the stock is currently owned by institutional investors and hedge funds.

Galectin Therapeutics Stock Performance

Galectin Therapeutics stock traded up $0.01 during mid-day trading on Wednesday, reaching $1.35. The company's stock had a trading volume of 3,967 shares, compared to its average volume of 318,698. The business's 50 day simple moving average is $1.47 and its 200 day simple moving average is $1.85. Galectin Therapeutics Inc. has a 12 month low of $0.73 and a 12 month high of $3.87. The company has a market capitalization of $84.98 million, a price-to-earnings ratio of -1.84 and a beta of 0.79.

Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last issued its earnings results on Monday, March 31st. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.03). As a group, sell-side analysts expect that Galectin Therapeutics Inc. will post -0.73 EPS for the current year.

Analysts Set New Price Targets

GALT has been the topic of a number of recent analyst reports. StockNews.com cut shares of Galectin Therapeutics from a "hold" rating to a "sell" rating in a research report on Monday, December 30th. HC Wainwright restated a "neutral" rating on shares of Galectin Therapeutics in a report on Wednesday, April 2nd.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.